دورية أكاديمية
Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer.
| العنوان: | Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. |
|---|---|
| المؤلفون: | Peng Z; Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Li Z; Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, China., Gao J; Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Lu M; Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Gong J; Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Tang ET; Biostatistical Science, Amgen Inc., Shanghai, China., Oliner KS; Molecular Sciences, Amgen Inc., Thousand Oaks, California., Hei YJ; Global Development, Amgen Inc., Shanghai, China., Zhou H; Medical Department, Amgen Inc., Shanghai, China., Shen L; Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China. lin100@medmail.com.cn. |
| المصدر: | Molecular cancer therapeutics [Mol Cancer Ther] 2015 Nov; Vol. 14 (11), pp. 2634-41. Date of Electronic Publication: 2015 Sep 01. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : American Association for Cancer Research, Inc., c2001- |
| مواضيع طبية MeSH: | Gene Amplification*, Esophagogastric Junction/*metabolism , Proto-Oncogene Proteins c-met/*genetics , Stomach Neoplasms/*genetics, Asian People/genetics ; China ; Drug Therapy/methods ; Esophagogastric Junction/drug effects ; Esophagogastric Junction/pathology ; Female ; Follow-Up Studies ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Male ; Middle Aged ; Neoplasm Metastasis ; Phosphorylation ; Prognosis ; Proto-Oncogene Proteins c-met/metabolism ; Stomach Neoplasms/ethnology ; Stomach Neoplasms/metabolism ; Survival Analysis ; Treatment Outcome |
| مستخلص: | MET and its sole ligand, hepatocyte growth factor (HGF), are promising targets in gastric and gastroesophageal junction cancer. We evaluated whether MET protein expression or MET gene amplification is prognostic for overall survival (OS) in Chinese patients with advanced gastric or gastroesophageal junction cancer. Archival formalin-fixed, paraffin-embedded tumor samples from patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer enrolled in clinical trials at Peking University Cancer Hospital from 2008 to 2010 were assessed for MET and phospho-MET (p-MET) expression by immunohistochemistry and MET amplification by FISH. MET-positive expression was defined as membrane protein staining in ≥25% of tumor cells. MET amplification was defined as MET:centromere 7 ratio >2.0. We tested the association of MET status with clinical characteristics and OS, and also evaluated the association between expression and amplification. One hundred sixty-eight patients were eligible. Of the evaluable samples, 53 of 137 (39%) were MET positive, eight of 134 (6%) were p-MET positive, and eight of 113 (7%) were MET amplified. Neither MET expression nor MET amplification were associated with clinical characteristics, except Lauren classification (P = 0.04); MET amplification was associated with diffuse type. No significant OS difference was observed between MET-positive and MET-negative populations, regardless of first-line chemotherapy received. In 95 evaluable patients, MET expression was significantly associated with MET amplification (P < 0.001); all MET-amplified tumor samples showed some MET expression. In 96 evaluable patients, p-MET positivity was significantly associated with MET amplification (P < 0.001). Further evaluation in larger and independent sample sets is warranted to confirm our findings. (©2015 American Association for Cancer Research.) |
| المشرفين على المادة: | EC 2.7.10.1 (MET protein, human) EC 2.7.10.1 (Proto-Oncogene Proteins c-met) |
| تواريخ الأحداث: | Date Created: 20150903 Date Completed: 20160906 Latest Revision: 20221207 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1158/1535-7163.MCT-15-0108 |
| PMID: | 26330547 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-8514 |
|---|---|
| DOI: | 10.1158/1535-7163.MCT-15-0108 |